<DOC>
	<DOCNO>NCT00457119</DOCNO>
	<brief_summary>This 2 step study aim establish tolerable dose level regimen RAD001 patient advance NCLC previously treat systemic therapy . In step 1 study , RAD 001 give combination carboplatin paclitaxel Step 2 RAD001 give combination carboplatin , paclitaxel bevacizumab</brief_summary>
	<brief_title>Combination RAD001 With Carboplatin , Paclitaxel Bevacizumab Non-small-cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description>This two-step , open-label , multi-center , dose escalation Phase 1 study RAD001 administer combination carboplatin paclitaxel ( CP ) Step 1 well carboplatin , paclitaxel , bevacizumab ( CPB ) Step 2 patient advanced ( unresectable metastatic ) NSCLC treat previously systemic therapy advance disease</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Age 18 year Advanced Non Small Cell Lung Cancer ( Stage IIIB/IV ) Ability perform normal daily function Exclusion criterion : Chronic steroid treatment Prior treatment chemotherapy advance lung cancer Prior treatment mTOR inhibitor Active bleed condition , skin condition , gastrointestinal disorder , mouth ulcer , eye condition , chronic liver kidney disorder , uncontrolled diabetes , infection severe medical condition Known sensitivity platinum compound , taxanes bevacizumab Other cancer within past 5 year Pregnant breastfeeding woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Advanced Lung Cancer</keyword>
	<keyword>RAD</keyword>
	<keyword>RAD001</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>bevacizumab</keyword>
</DOC>